Back Home About Us

Long-time Researcher Discusses Myths About HIV Pathogenesis, Treatment, and Cure

Over the 3 decades of the epidemic a number of misconceptions have arisen about HIV infection, how the immune system fights the virus, and how best to treat and potentially cure it, along with a number of important questions that remain unanswered, according to an opinion article in the April 13 advance edition of Trends in Molecular Medicine by Jay Levy from the University of California at San Francisco, one of the first researchers to study HIV. The trend toward earlier antiretroviral therapy and treatment-as-prevention are among the issues he contests.

alt

Read more:

CROI 2015: Daily PrEP Leads to Better Adherence and Protective Drug Levels in Women

HIV-negative African women assigned to take once-daily Truvada for HIV pre-exposure prophylaxis (PrEP) achieved better adherence than those assigned to take PrEP twice-weekly or before and after sex, according to findings from the HPTN 076 trial presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

DHHS Updates Antiretroviral Treatment Guidelines for Adults and Children

The U.S. Department of Health and Human Services (DHHS) has released updated versions of its antiretroviral treatment guidelines for adults and adolescents, and for children with HIV. The new adult guidelines include revised recommendations for first-line antiretroviral therapy (ART) as well as management of treatment-experienced patients. The revised pediatric guidelines include a discussion of very early treatment for HIV-infected infants.

alt

Read more:

Women in PrEP Trial Feared Having to Leave Study if They Reported Low Adherence

Post-study interviews and computer questionnaires conducted with former participants in the Fem-PrEP trial of pre-exposure prophylaxis (PrEP) that reported zero effectiveness show that the women concealed their low adherence because -- despite reassurances from researchers -- they feared they would be asked to leave the study, according to a report in the April 2015 Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

April 10 is National Youth HIV & AIDS Awareness Day

April 10 is the third observation of National Youth HIV & AIDS Awareness Day (NYHAAD), an opportunity to promote education and raise awareness about the epidemic among young people in the U.S.

alt

Read more:

HIV Risk Behavior Remains Common Among People Who Inject Drugs in U.S.

An analysis from the CDC's National HIV Behavioral Surveillance system found that 11% of injection drug users in 20 U.S. cities were HIV-positive in 2012, according to a report in the March 20 Morbidity and Mortality Weekly Report. One-third of the interviewees reported sharing used injection equipment, putting them at risk for acquiring HIV and hepatitis B and C, while a majority reported sex without condoms.

alt

Read more:

Some Providers Remain Reluctant to Prescribe HIV Pre-Exposure Prophylaxis

Despite a growing body of evidence showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, is highly effective for HIV prevention, less than half of surveyed healthcare providers are likely to prescribe it for at-risk heterosexuals or people who inject drugs -- though the likelihood approaches 80% for gay men with HIV-positive partners -- according to a study published in the April edition of HIV Specialist, the magazine of the American Academy of HIV Medicine (AAHIVM).

alt

Read more:

CROI 2015: Cardiovascular Risk Factors for HIV-Positive People

TEXT

alt

Read more:

Most Children with HIV Experience CD4 Cell Recovery after Starting Antiretroviral Therapy

Children with perinatal HIV infection who start antiretroviral therapy (ART) typically experience good recovery of CD4 T-cells, but the likelihood of reaching 500 cells/mm3 or more is higher for those with less immune suppression prior to treatment initiation, according to a study published in the March 27 edition of AIDS.

alt

Read more: